No significant association was found between TB development and IBD phenotype or isoniazid use.<h4>Conclusion</h4>Despite latent TB screening and prophylactic treatment, patients receiving TNF-α antagonists remain at risk of developing active TB, with a latent TB prevalence of 50.4% and an active TB incidence of 1.7%. This evidence concerns the gene TNF and inflammatory bowel disease.